Marco Meglio

The drug was proven to be efficacious and generally well tolerated in adults with newly diagnosed epilepsy.

Patients who were administered levetiracetam, fosphenytoin, or valproate saw similar improvements in seizure reduction and responsiveness.

Top line results from the phase 3 trial of sovateltide in patients with acute cerebral ischemic stroke are expected by mid-2020.

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.

The private-public partnership aims to share patient data in hopes of uncovering new biomarkers related to Parkinson disease.

Fenfluramine is set for priority review by the FDA with a PDUFA date of March 25, 2020.

Results from the phase 3 EVOLVE-MS-2 study demonstrate superior tolerability for now-approved diroximel fumarate compared to dimethyl fumarate.

The phase 1/2 trial seeks to will assess the safety and efficacy of mesenchymal stem cells for the treatment of Alzheimer disease.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, sat down to discuss the challenges faced in diagnosing Lewy body dementia.

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.

A study comparing 2 doses of minocycline falls short as the drug failed to slow progression of cognitive or functional decline in people with AD.

A lower target for low-density lipoprotein is associated with a greater reduction in cardiovascular events after ischemic stroke over a higher LDL target.

Benjamin Walter, MD, medical director of the Deep Brain Stimulation Program at Cleveland Clinic shared his personal experience with deep brain stimulation and focused ultrasound and the potential of the procedures.

Data from a new study demonstrates valbenazine’s ability to effectively reduce TD symptoms over a long-term period.

Patients in small-scale trial experienced a drastic reduction in monthly headache days after just 1 dose of erenumab.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

Patients with spinal muscular atrophy types 2 or 3 saw improvements in motor function after receiving risdiplam; data will be presented at an upcoming medical congress.

EIP Pharma also announced results from the REVERSE-SD study that examined neflamapimod in early stage Alzheimer disease.

The robotic platform used in various neurosurgeries was identified for a class 1 recall due to a software error which can lead to robotic arm malfunction.

The phase 2/3 trials will end after a futility analysis suggested that the drug is not likely to show a clinical benefit.

Imad Najm, MD, details how advanced telemedicine technology has created a paradigm shift in the way physicians see and treat patients at Cleveland Clinic and around the world.

Data show patients with high frequency episodic migraine are comparable to those with chronic migraine in regard to chronicity and disability.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

A phase 3 study of celecoxib oral solution showed statistically significant improvements in the acute treatment of episodic migraine.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Study results show that deflazacort tops prednisone across multiple checkpoints in patients with Duchenne muscular dystrophy.

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.

The drug is now approved to treat pediatric patients with both upper and lower limb spasticity, excluding spasticity caused by cerebral palsy.

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.